Literature DB >> 1339192

Receptor changes and LTP: an analysis using aniracetam, a drug that reversibly modifies glutamate (AMPA) receptors.

U Staubli1, J Ambros-Ingerson, G Lynch.   

Abstract

The hypothesis that long-term potentiation (LTP) involves receptor modifications was tested with aniracetam, a nootropic drug that selectively increases currents mediated by the AMPA subclass of glutamate receptors. Aniracetam had different effects on the waveform of synaptic potentials in hippocampus before and after induction of LTP: (1) the drug caused a slight reduction (or delay) of the initial segment of the response after LTP; and (2) the facilitatory effects of aniracetam occurred at a later time point in the response after LTP than before. The interactions between LTP and aniracetam were still present when synaptic responses were greatly reduced by partial blockade of postsynaptic receptors and were not reproduced by increasing release or the number of stimulated synapses. A mathematical treatment of synaptic currents produced the following results: (1) if aniracetam facilitates AMPA receptor currents simply by reducing desensitization, then its complex interaction with LTP emerges when potentiation changes the kinetic and conductance properties of receptor channels; (2) if aniracetam also significantly increases conductance, then the experimental data can be reproduced by modeling LTP as an increase in channel conductance alone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1339192     DOI: 10.1002/hipo.450020107

Source DB:  PubMed          Journal:  Hippocampus        ISSN: 1050-9631            Impact factor:   3.899


  7 in total

Review 1.  Synthesis of models for excitable membranes, synaptic transmission and neuromodulation using a common kinetic formalism.

Authors:  A Destexhe; Z F Mainen; T J Sejnowski
Journal:  J Comput Neurosci       Date:  1994-08       Impact factor: 1.621

2.  Involvement of the secretory pathway for AMPA receptors in NMDA-induced potentiation in hippocampus.

Authors:  G Broutman; M Baudry
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

3.  Interactions of 2,3-benzodiazepines and cyclothiazide at AMPA receptors: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.

Authors:  G Rammes; D Swandulla; G L Collingridge; S Hartmann; C G Parsons
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Channel gating kinetics and synaptic efficacy: a hypothesis for expression of long-term potentiation.

Authors:  J Ambros-Ingerson; G Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

Review 5.  Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data.

Authors:  Mark D Black
Journal:  Psychopharmacology (Berl)       Date:  2005-01-26       Impact factor: 4.530

Review 6.  Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders.

Authors:  C R Lee; P Benfield
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

7.  Physiological signature of a novel potentiator of AMPA receptor signalling.

Authors:  Blanka R Szulc; Stephen T Hilton; Arnaud J Ruiz
Journal:  Mol Cell Neurosci       Date:  2018-07-22       Impact factor: 4.314

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.